FiercePharma

AbbVie's Skyrizi proves a worthy Humira successor with nearly matching sales ahead of potential UC nod

AbbVie’s immunology heirs Skyrizi and Rinvoq are proving booming growth to make up for once-king Humira’s continuous sales slide. With an upcoming FDA decision for Skyrizi and a new edge over a major ...
Nasdaq

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

NORTH CHICAGO, Ill., March 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating ...
Seeking Alpha

U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease

NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ -- AbbVie (ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately to ...
FiercePharma

AbbVie's Skyrizi snatches sales crown from Humira as company lifts full-year profit guidance

It’s a new era for AbbVie. For the first time in years, the company has a new top sales driver as Skyrizi has overtaken Humira in quarterly sales. Humira heir Skyrizi has been slowly creeping up on ...
Seeking Alpha

AbbVie Already Has The Next Humira

AbbVie delivered Y/Y growth in the second quarter despite Humira’s decline, with Skyrizi and Rinvoq as key growth drivers, achieving 45% and 56% Y/Y growth, respectively. I expect Skyrizi to become a ...
Healthline

Skyrizi: How It Works

Skyrizi (risankizumab-rzaa) is a prescription drug used to treat certain autoimmune conditions, including plaque psoriasis and Crohn’s disease. It works by attaching to specific proteins in your ...

This startup’s psoriasis drug studies have lifted its stock

Phase 1 studies showed that one shot of ORKA-001 lasted long enough to allow dosing twice-a-year—or even once-a-year.
Benzinga.com

AbbVie Jumps After Q4 Earnings Beat, Skyrizi And Rinvoq Boom Offsets Humira Decline

AbbVie Inc. (NYSE:ABBV) shares are trading higher on Friday. The company reported fourth-quarter adjusted earnings per share of $2.16, beating the street view of $2.11. Quarterly sales of $15.102 ...
Benzinga.com

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

AbbVie Inc. (NYSE: ABBV) reported fourth-quarter 2025 sales of $16.62 billion on Wednesday, beating the consensus of $16.42 billion. Sales increased 10% on a reported basis or 9.5% on an operational ...
Nasdaq

Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?

AbbVie ABBV expects to return to robust revenue growth in 2025, just two years after losing U.S. exclusivity for its flagship drug, Humira. The drug, which went off-patent in January 2023, saw ...
St. Louis American

U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie’s Portfolio Across Inflammatory Bowel Disease

NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately ...